Table 3.

Comparison of observed and predicted TTP and PFS at 24 months

Study	Condition	Observed median TTP (months)*	Predicted median TTP (months)†	Observed PFS at 24 months*	Predicted PFS at 24 months†
Pivotal [15, 17] (A)	All patients	9.0	8.6 (7.1, 10.1)	–	–
Weng [22] (B)	Fx	5.6	7.6 (5.7, 10.4)	0.17	0.081 (0.024, 0.17)
	VV	17.8	19.2 (11.7, 30.0)	0.45	0.40 (0.20, 0.61)
Van Oers [14] (C)	R-CHOP + observation	21.6	21.1 (18.9, 27.7)	0.50	0.48 (0.40, 0.56)
	R-CHOP + maintenance	58.3	31.7 (25.4, 39.1)	0.61	0.59 (0.50, 0.65)
Cartron [20] (D)	Fx	16.4	17.1 (12.1, 23.3)	0.41	0.36 (0.25, 0.49)
	VV‡	>37.5 (not reached)	37.1	0.67	0.63

Data are presented as

^*median and

^†median (90% CI).

^‡For VV patients, median TTP was not reached at the end of the follow-up.

Because of a small number of subjects, 90% CI was too large to be displayed. TTP, times to progression; PFS, progression-free survival; R-CHOP, rituximab, cyclophosphamide, vincristine, adriamycin and prednisone.